GSK (GSK) Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum summary
Event summary combining transcript, slides, and related documents.
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum summary
23 Sep, 2026R&D strategy and organizational scope
End-to-end accountability for respiratory, immunology, and inflammation R&D, from discovery to product approval.
Integration of translational development sciences across oncology, specialty, and vaccines, with a focus on leveraging opportunities in China.
Emphasis on genetics, genomics, single-cell technologies, and real-world evidence to inform target-trait pairings and development.
Respiratory and immunology pipeline evolution
Focus on ultra-long-acting biologics to improve patient persistence and reduce treatment burden in asthma.
Diversification in COPD with new mechanisms, including ultra-long-acting TSLP, IL-33, PDE3/4 inhaled approaches, and siRNA programs.
Sophisticated patient stratification using biomarkers like eosinophil levels to guide therapy selection.
Combination approaches and mechanism-specific targeting to address different disease segments and comorbidities.
Clinical development and differentiation
IL-33 program designed as a potent ligand neutralizer, aiming for broader efficacy than ST2 receptor blockers.
Upcoming cardiopulmonary outcome study to evaluate benefits on hospitalizations and mortality in COPD, starting next year.
High confidence in long-acting TSLP based on strong phase II data and competitor insights, with multiple pivotal studies underway.
Latest events from GSK
- GBP 1.9bn savings and 22 Phase III starts fuel a >GBP 40bn 2031 sales ambition.GSK
J.P. Morgan UK Leaders Conference - Four- and six-month HIV regimens, pipeline launches and oncology aim to sustain growth through expiries.GSK
Jefferies Global Healthcare Conference - Biomarker-led R&D advances long-acting airway therapies and novel liver programs.GSK
3rd Annual Guggenheim Healthcare Innovation Conference - Specialty-led growth and pipeline investment support reaffirmed FY26 guidance.GSK
Q3 2026 - Oncology data highlighted gains across ADCs, immunotherapy and targeted therapies.GSK
ESMO 2026 Investor Briefing - 14% CER sales growth and upgraded outlooks to >£38bn sales by 2031.GSK
Q4 2023 - GBP 1.9bn in savings will fund pipeline growth, with oncology and specialty assets prioritized.GSK
Bank of America Global Healthcare Conference - Rapid portfolio growth and robust clinical data position oncology for major advances by 2031.GSK
Morgan Stanley 24th Annual Global Healthcare Conference - Accelerated R&D, pipeline reinvestment, and specialty focus drive growth and margin stability.GSK
Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference